(C) Daily Kos
This story was originally published by Daily Kos and is unaltered.
. . . . . . . . . .



Diabetes News: Ozempic Ups and Downs [1]

['This Content Is Not Subject To Review Daily Kos Staff Prior To Publication.']

Date: 2025-01-29

We keep finding more uses for semaglutide, which makes it all the more important that we rein in its cost. We saw last week that Medicare has put Ozempic and other semaglutide products on its list for the next round of price negotiations, to be wrapped up in 2026 regardless of the current maladministration’s meddling. The new prices would then go into effect in 2027.

The Ozempic debate: Large study reveals the good and the bad

Ozempic, Wegovy, Zepbound and other drugs often used for weight loss may help lower the risk of a wide range of health conditions, from diabetes to Alzheimer’s, according to a new study, but they also may come with risks like pancreatitis and stomach paralysis. The large observational study, published Monday in Nature Medicine, is the first of its kind to map the risks and benefits of drugs like Ozempic across 175 potential health outcomes, according to the authors. These health outcomes ranged from psychotic disorders, seizures and dementia to gastrointestinal disorders, hypotension and arthritis.

Mapping the effectiveness and risks of GLP-1 receptor agonists

We used a discovery approach to systematically map an atlas of the associations of GLP-1RA use versus each comparator with 175 health outcomes. Compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. There was an increased risk of gastrointestinal disorders, hypotension, syncope [fainting], arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis associated with GLP-1RA use compared to usual care. The results provide insights into the benefits and risks of GLP-1RAs and may be useful for informing clinical care and guiding research agendas. [emphasis added]

Stat+ [paywalled]:

Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study

Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes, an analysis of medical records found, supporting the case for further research of the blockbuster GLP-1 drug in neurodegenerative diseases. Among the over 1 million people with diabetes whose records were included in the study, the overall risk of developing Alzheimer’s was already very low. But researchers found that semaglutide, the scientific name of Ozempic, was associated with a 40% to 70% lower risk of an Alzheimer’s diagnosis over three years compared with other diabetes treatments such as insulin, metformin, SGLT2 inhibitors, and older GLP-1 drugs.

Stat+ [paywalled]: Study links Ozempic to higher risk of eye condition that can cause vision loss

[END]
---
[1] Url: https://www.dailykos.com/stories/2025/1/29/2299874/-Diabetes-News-Ozempic-Ups-and-Downs?pm_campaign=front_page&pm_source=more_community&pm_medium=web

Published and (C) by Daily Kos
Content appears here under this condition or license: Site content may be used for any purpose without permission unless otherwise specified.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/dailykos/

You are viewing proxied material from magical.fish. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.